0000000000736913

AUTHOR

Nelson Dusetti

0000-0002-6161-8483

showing 7 related works from this author

Response to "Is the Reg3α (HIP/PAP) Protein Really an Obesogenic Factor?"

2015

Peer Reviewed

Male0301 basic medicinePhysiologyClinical BiochemistryeducationMEDLINEPancreatitis-Associated ProteinsBiologyClinical biochemistry03 medical and health sciences0302 clinical medicineAnimalsHumansObesityPancreatitis-Associated ProteinsAnimalProteinMedicine (all)ProteinsCell BiologyBlood coagulation factorsBlood Coagulation Factors030104 developmental biology030220 oncology & carcinogenesisProteins metabolismImmunologyFemaleBlood Coagulation FactorHuman
researchProduct

Clinical evaluation of pancreatitis-associated protein as a serum marker of hepatocellular carcinoma: Comparison with α-fetoprotein

1998

This study evaluated the significance of serum pancreatitis-associated protein (PAP) assay, as a marker of hepatocellular carcinoma (HCC), in comparison and combined with α-fetoprotein (AFP) assay. Sixty-five patients with HCC, 59 with liver cirrhosis (LC) and 68 asymptomatic controls (C) were studied. PAP and AFP values significantly increased from C to LC and HCC group (p < 0.0001). The area under receiver-operating characteristic (ROC) curve for the two markers was not statistically different. At 100% specificity, ROC analysis gave a cut-off level for AFP of 166 IU/l with 40% sensitivity, and a cut-off level of 240 µg/l for PAP with 23% sensitivity. Diagnostic accuracy of combined AFP…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyCirrhosisCarcinoma HepatocellularPancreatitis-Associated ProteinsAsymptomaticSensitivity and SpecificityAntigens NeoplasmBiomarkers TumorMedicineHumansLectins C-TypeneoplasmsTumor markerAgedbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasedigestive system diseasesLogistic ModelsOncologyHepatocellular carcinomaPancreatitisFemalealpha-Fetoproteinsmedicine.symptombusinessClinical evaluationSerum markersAcute-Phase Proteins
researchProduct

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma

2019

PDAC is one of the most heterogeneous cancers with low chemotherapeutic sensitivity due to a dense stroma, a weak vasculature and significant biological aggressivity. In cancer, suppressive immune checkpoints are often hyper-activated to ensure an effective evasion of tumor cells from immune surveillance. These immune checkpoints include in part, the B7/butyrophilin-like receptors such as butyrophilin sub-family 3A/CD277 receptors (BTN3A), the B and T lymphocyte attenuator (BTLA) belonging to the B7-like receptors and the programmed death protein (PD-1) with its ligand PD-L1. We evaluated the plasma level of these markers in 32 PDAC patients (learning cohort) by ad hoc developed ELISA’s and…

0301 basic medicinelcsh:Immunologic diseases. Allergybutyrophilin 3Aendocrine system diseases[SDV]Life Sciences [q-bio]Immunologypancreatic cancerBTLA[SDV.CAN]Life Sciences [q-bio]/Cancerprogrammed cell death-1B and T lymphocyte attenuatorlcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemStromaPancreatic cancerPD-L1medicineImmunology and Allergyprogrammed cell death ligand-1Original Researchbiologybusiness.industryCancer[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdigestive system diseasesImmune checkpoint3. Good health030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchbiology.proteinoutcomeAdenocarcinomaImmune checkpointbusinesslcsh:RC581-607[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.

2007

Pancreatic cancer is a disease with an extremely poor prognosis. Tumor protein 53-induced nuclear protein 1 ( TP53INP1 ) is a proapoptotic stress-induced p53 target gene. In this article, we show by immunohistochemical analysis that TP53INP1 expression is dramatically reduced in pancreatic ductal adenocarcinoma (PDAC) and this decrease occurs early during pancreatic cancer development. TP53INP1 reexpression in the pancreatic cancer-derived cell line MiaPaCa2 strongly reduced its capacity to form s.c., i.p., and intrapancreatic tumors in nude mice. This anti-tumoral capacity is, at least in part, due to the induction of caspase 3-mediated apoptosis. In addition, TP53INP1 −/− mouse embryonic…

Settore MED/06 - Oncologia MedicaTransplantation HeterologousGene ExpressionMice NudeMicePancreatic tumorPancreatic cancerCell Line TumormicroRNAGene expressionmedicineAnimalsHumansRNA NeoplasmNuclear proteinCaspaseHeat-Shock ProteinsMice KnockoutMultidisciplinarybiologyBase Sequenceapoptosis pancreatic cancer ponasterone A tumor suppressor micro RNANuclear ProteinsBiological Sciencesmedicine.diseaseTransplantationPancreatic NeoplasmsMicroRNAsCell Transformation NeoplasticApoptosisCancer researchbiology.proteinTumor Suppressor Protein p53Carrier ProteinsNeoplasm TransplantationCarcinoma Pancreatic DuctalProceedings of the National Academy of Sciences of the United States of America
researchProduct

PAP/HIP Protein Is an Obesogenic Factor

2013

In this article we report the obesogenic role of the acute phase protein PAP/HIP. We found that the transgenic TgPAP/HIP mice develop spontaneous obesity under standard nutritional conditions, with high levels of glucose, leptin, and LDL and low levels of triglycerides and HDL in blood. Accordingly, PAP/HIP-deficient mice are skinny under standard nutritional conditions. We also found that expression of PAP/HIP is induced in intestinal epithelial cells in response to gavage with olive oil and this induction is AG490 sensitive. We demonstrated that incubation of 3T3-L1 preadipocytes with a low concentration as 1 ng/ml of recombinant PAP/HIP results in accelerated BrdU incorporation in vitro.…

medicine.medical_specialtyPhysiologybusiness.industryLeptinMEK inhibitorTransgeneClinical BiochemistryAcute-phase proteinAdipose tissueCell Biologymedicine.diseaseObesityIn vitroEndocrinologyInternal medicinemedicinePancreatitis-Associated ProteinsbusinessJournal of Cellular Physiology
researchProduct

PAP/HIP protein is an obesogenic factor

2013

In this article we report the obesogenic role of the acute phase protein PAP/HIP. We found that the transgenic TgPAP/HIP mice develop spontaneous obesity under standard nutritional conditions, with high levels of glucose, leptin, and LDL and low levels of triglycerides and HDL in blood. Accordingly, PAP/HIP-deficient mice are skinny under standard nutritional conditions. We also found that expression of PAP/HIP is induced in intestinal epithelial cells in response to gavage with olive oil and this induction is AG490 sensitive. We demonstrated that incubation of 3T3-L1 preadipocytes with a low concentration as 1ng/ml of recombinant PAP/HIP results in accelerated BrdU incorporation in vitro. …

Transgenic micePAP/HIPSevere obesity
researchProduct

BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

2017

Vγ9Vδ2 T cells are anti-tumor immune effectors of growing interest in cancer including Pancreatic Ductal Adenocarcinoma (PDAC), an especially aggressive cancer characterized by a hypoxic and nutrient-starved immunosuppressive microenvironment. Since Butyrophilin 3 A (BTN3A) isoforms are critical activating molecules of Vγ9Vδ2 T cells, we set out to study BTN3A expression under both basal and stress conditions in PDAC primary tumors, and in novel patient-derived xenograft and PDAC-derived cell lines. BTN3A2 was shown to be the most abundant isoform in PDAC and was stress-regulated. Vγ9Vδ2 T cells cytolytic functions against PDAC required BTN3A and this activity was strongly enhanced by the a…

0301 basic medicineOncologylcsh:Immunologic diseases. Allergymedicine.medical_specialtyPancreatic ductal adenocarcinomaendocrine system diseasesmedicine.medical_treatment[SDV]Life Sciences [q-bio]Immunologybtn3apancreatic ductal adenocarcinomalcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemInternal medicinemedicineImmunology and AllergyComputingMilieux_MISCELLANEOUSbusiness.industrycd277Aggressive cancerCancerPrognosis MarkerImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensbutyrophilin 3 adigestive system diseases3. Good health[SDV] Life Sciences [q-bio]030104 developmental biologyOncology030220 oncology & carcinogenesisimmunotherapybusinesslcsh:RC581-607Research Article
researchProduct